Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Darzalex in combination with lenalidomide and dexamethasone is for people who are ineligible for an autologous stem cell transplant.
The Food and Drug Administration may approve the next site-agnostic treatment in August.
An immunocompromised patient died from invasive infections after an investigational fecal microbiota transplant.
New initiative will help health care providers navigate the process of submitting expanded access requests.
People of all skin colors are potentially at risk for sunburn and other harmful effects of UV radiation, so always protect yourself.
Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.
There are now five targeted therapies for the most common type of liver cancer.
Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.
The FDA is proposing updates to mammography regulations to reflect advances in technology and processes. How could these changes affect you?
Overall, few people actually sign up for and participate in trials, and those who do participate don’t always represent the U.S. population.
Use by adolescents poses a concern: Medical experts say some users will transition to tobacco products, which are closely linked to cancer.
The FDA wants to help separate fact from fiction to when it comes to methods used to quit smoking.
Proposed rule would require breast density reporting and enhance the FDA’s ability to enforce compliance.
The agency has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database.
Ned Sharpless has been appointed interim head of the regulatory agency after the unexpected resignation of the commissioner.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.